Susquehanna International Group’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-28,700
Closed -$35K 10464
2018
Q3
$35K Buy
+28,700
New +$32.1K ﹤0.01% 8917
2017
Q2
Sell
-32,000
Closed -$60K 10158
2017
Q1
$60K Sell
32,000
-344,600
-92% -$1.56M ﹤0.01% 8556
2016
Q4
$1.95M Buy
+376,600
New +$1.98M ﹤0.01% 4117
2016
Q1
Sell
-23,500
Closed -$141K 9992
2015
Q4
$141K Buy
23,500
+1,900
+9% +$12.9K ﹤0.01% 8694
2015
Q3
$169K Buy
21,600
+11,500
+114% +$89.1K ﹤0.01% 8833
2015
Q2
$62K Buy
+10,100
New +$78.3K ﹤0.01% 9823
2014
Q4
Sell
-87,400
Closed -$454K 10315
2014
Q3
$454K Sell
87,400
-14,200
-14% -$91.6K ﹤0.01% 7389
2014
Q2
$789K Buy
101,600
+18,400
+22% +$130K ﹤0.01% 6556
2014
Q1
$581K Buy
83,200
+30,600
+58% +$239K ﹤0.01% 6497
2013
Q4
$315K Buy
+52,600
New +$344K ﹤0.01% 7509

Other funds holding GNMX

Susquehanna International Group's GNMX Position: Q2 2019 in Review

Susquehanna International Group sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2019, closing a stake of 127,313 shares — an estimated $25K sold.

Susquehanna International Group first reported a position in GNMX in Q1 2014 and held it in 13 quarters. The position peaked at $412K in Q1 2015. 29 funds tracked by Wall St. Rank hold GNMX as of Q2 2019.

  • Susquehanna International Group reported no remaining Aevi Genomic Medicine Inc position as of Q2 2019 after selling out during the quarter.
  • Susquehanna International Group sold 127,313 Aevi Genomic Medicine Inc shares in Q2 2019, an estimated $25K.
  • Susquehanna International Group first reported a position in Aevi Genomic Medicine Inc in Q1 2014 and held it in 13 quarters.
  • Susquehanna International Group's Aevi Genomic Medicine Inc position peaked at $412K in Q1 2015.
  • 29 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2019.

Based on Susquehanna International Group's 13F filing for Q2 2019, filed 14 Aug 2019.